ECSP044998A - Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina - Google Patents

Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina

Info

Publication number
ECSP044998A
ECSP044998A EC2004004998A ECSP044998A ECSP044998A EC SP044998 A ECSP044998 A EC SP044998A EC 2004004998 A EC2004004998 A EC 2004004998A EC SP044998 A ECSP044998 A EC SP044998A EC SP044998 A ECSP044998 A EC SP044998A
Authority
EC
Ecuador
Prior art keywords
pirimidinas
pirrolo
inhibition
agents
cysteine proteases
Prior art date
Application number
EC2004004998A
Other languages
English (en)
Inventor
Claudia Betschart
Naoki Teno
Osamu Irie
Rene Lattmann
Martin Missbach
Junichi Sakaki
Kenji Hayakawa
Genji Iwasaki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP044998A publication Critical patent/ECSP044998A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona compuestos de la fórmula I o una sal o éster farmacéuticamente aceptable del mismo, en donde los símbolos tienen los significados definidos, que son inhibidores de la catepsina K y encuentran uso farmacéuticamente para el tratamiento de enfermedades y condiciones médicas en las cuales está involucrada la catepsina K, por ejemplo varios trastornos que incluyen inflamación, artritis reumatoide, osteoartritis, osteoporosis y tumores
EC2004004998A 2001-08-30 2004-03-01 Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina ECSP044998A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP044998A true ECSP044998A (es) 2004-04-28

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004998A ECSP044998A (es) 2001-08-30 2004-03-01 Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina

Country Status (29)

Country Link
US (2) US7452886B2 (es)
EP (1) EP1423391B8 (es)
JP (1) JP4629334B2 (es)
KR (1) KR100695845B1 (es)
CN (1) CN100372849C (es)
AR (1) AR036374A1 (es)
AT (1) ATE326469T1 (es)
AU (1) AU2002333760B2 (es)
BR (1) BR0212226A (es)
CA (1) CA2458684C (es)
CY (1) CY1105573T1 (es)
DE (1) DE60211530T2 (es)
DK (1) DK1423391T3 (es)
EC (1) ECSP044998A (es)
ES (1) ES2262888T3 (es)
GB (1) GB0121033D0 (es)
HU (1) HUP0401301A3 (es)
IL (3) IL160367A0 (es)
MX (1) MXPA04001935A (es)
MY (1) MY157368A (es)
NO (1) NO328890B1 (es)
NZ (1) NZ531343A (es)
PE (1) PE20030418A1 (es)
PL (1) PL368280A1 (es)
PT (1) PT1423391E (es)
RU (1) RU2331644C2 (es)
TW (1) TWI297690B (es)
WO (1) WO2003020721A1 (es)
ZA (1) ZA200401042B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
TWI376363B (en) 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
WO2004092169A1 (ja) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
WO2004096227A1 (en) * 2003-04-28 2004-11-11 Novartis Ag Pharmaceutical compositon comprising a cathepsin s inhibitor and an opioid
EP1620421B1 (en) * 2003-04-30 2009-06-24 Bayer CropScience AG Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
WO2005023810A1 (en) * 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
EP1716125B1 (en) 2004-02-18 2013-06-19 AstraZeneca AB Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
JPWO2005085210A1 (ja) * 2004-03-10 2008-01-17 小野薬品工業株式会社 ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
EP1756109B1 (en) 2004-05-03 2016-07-13 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
JP5135795B2 (ja) 2004-08-27 2013-02-06 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
RU2424234C2 (ru) * 2005-08-05 2011-07-20 Ибриженикс Са Новые ингибиторы цистеиновых протеаз и их терапевтическое применение
AU2006286489B2 (en) 2005-09-01 2012-08-09 Ares Trading S.A. Treatment of optic neuritis
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
CA2630492C (en) * 2005-12-05 2015-04-14 Incyte Corporation Spiro-lactam compounds
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
JP2010503656A (ja) 2006-09-13 2010-02-04 アストラゼネカ アクチボラグ スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7960422B2 (en) 2007-10-19 2011-06-14 Astrazeneca Ab Pharmaceutically active compounds containing tetrazolyl and triazolyl rings
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
DK2448938T5 (en) 2009-06-29 2015-10-05 Incyte Corp Pyrimidinones AS PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
CA2785716A1 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
US9115126B2 (en) 2010-01-15 2015-08-25 Merck Sharp & Dohme B.V. 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
HRP20170285T1 (hr) 2011-09-02 2017-04-21 Incyte Holdings Corporation Heterociklilamini kao inhibitori pi3k
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
PT2840083T (pt) * 2012-04-17 2017-11-08 Astellas Pharma Inc Composto heterocíclico aromático bicíclico azotado
EP2859120B1 (en) 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis and prognosis of lung cancer metastasis
ES2744244T3 (es) 2012-10-12 2020-02-24 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
CN105980576B (zh) 2013-10-09 2021-07-16 生物医学研究机构基金会 用于源自乳腺癌的骨转移癌的预后和治疗的方法
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016092524A1 (en) 2014-12-11 2016-06-16 Inbiomotion S.L. Binding members for human c-maf
MX373232B (es) 2015-02-27 2020-05-08 Incyte Holdings Corp Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación.
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
KR102571924B1 (ko) 2016-05-25 2023-08-28 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
CN111565725A (zh) 2017-11-22 2020-08-21 生物运动有限公司 基于c-maf状态的乳腺癌的治疗性处理
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2022226166A1 (en) * 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
KR20240090633A (ko) * 2021-12-01 2024-06-21 에스티팜 주식회사 트리아졸로피리미디논 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270922A (es) * 1960-11-02
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
PT970084E (pt) * 1997-03-19 2003-10-31 Abbott Gmbh & Co Kg Pirrolo¬2,3d|pirimidinas e sua utilizacao como inibidores da tirosina-cinase
WO2000000201A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company BICYCLIC sPLA2 INHIBITORS
HUP0200403A3 (en) * 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg Pyrrolopyrimidines as protein kinase inhibitors, pharmaceutical compositions containing them and their use
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
AU2001247589A1 (en) * 2000-03-20 2001-10-03 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
CN1440393A (zh) 2000-04-28 2003-09-03 田边制药株式会社 环状化合物

Also Published As

Publication number Publication date
JP2005502683A (ja) 2005-01-27
US20090054467A1 (en) 2009-02-26
IL198643A (en) 2010-12-30
EP1423391B1 (en) 2006-05-17
AU2002333760B2 (en) 2007-01-04
CN1549817A (zh) 2004-11-24
NO328890B1 (no) 2010-06-07
RU2331644C2 (ru) 2008-08-20
ATE326469T1 (de) 2006-06-15
KR100695845B1 (ko) 2007-03-20
MXPA04001935A (es) 2004-06-15
DE60211530D1 (de) 2006-06-22
RU2004109815A (ru) 2005-10-20
HUP0401301A2 (hu) 2004-10-28
CA2458684A1 (en) 2003-03-13
MY157368A (en) 2016-06-15
TWI297690B (en) 2008-06-11
DE60211530T2 (de) 2006-12-21
WO2003020721A1 (en) 2003-03-13
HK1072254A1 (zh) 2005-08-19
CY1105573T1 (el) 2010-07-28
DK1423391T3 (da) 2006-09-25
CN100372849C (zh) 2008-03-05
US7452886B2 (en) 2008-11-18
PT1423391E (pt) 2006-09-29
IL160367A (en) 2009-12-24
ES2262888T3 (es) 2006-12-01
EP1423391A1 (en) 2004-06-02
PE20030418A1 (es) 2003-06-12
US20050054851A1 (en) 2005-03-10
JP4629334B2 (ja) 2011-02-09
HUP0401301A3 (en) 2008-03-28
PL368280A1 (en) 2005-03-21
KR20040029123A (ko) 2004-04-03
NO20041180L (no) 2004-03-19
AR036374A1 (es) 2004-09-01
EP1423391B8 (en) 2007-12-12
IL160367A0 (en) 2004-07-25
BR0212226A (pt) 2004-08-17
CA2458684C (en) 2009-04-07
ZA200401042B (en) 2004-10-25
GB0121033D0 (en) 2001-10-24
NZ531343A (en) 2006-01-27

Similar Documents

Publication Publication Date Title
ECSP044998A (es) Pirrolo pirimidinas como agentes para la inhibicion de proteasas de cisteina
ATE361300T1 (de) Derivate von heteroarylnitrilverbindungen
DK1601677T3 (da) Spirosubstituerede pyrrolopyrimidiner
PL367821A1 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
SV2004001414A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion. pc20535
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201691142A1 (ru) Ингибиторы мек и способы их применения
PA8601901A1 (es) Pirazoles como inhibidores de factor de necrosis tumoral
IS8175A (is) Píperasín afleiður og aðferðir við notkun þeirra
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
DE602004016850D1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
ATE438618T1 (de) Inhibitoren von humanem adam-10
ECSP024244A (es) Uso de (z)-2-cyano-3-hydroxy-but-2-enoic acid(4´-trifluoromethylphenyl)-amide para el tratamiento de la esclerosis múltiple
SE0002739D0 (sv) New use
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
ECSP044989A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4-amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflamaciones y otras enfermedades
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
ECSP993018A (es) Nuevos inhibidores de proteasas, particularmente inhibidores de cisteina y serina proteasas
DOP2003000702A (es) Inhibidores de la cisteina proteasa catepsina
ECSP993211A (es) Inhibidores de proteasas vi
ITMI20030258A1 (it) Composizioni per il trattamento di ferite corneali
AR028558A1 (es) MALONAMIDAS CíCLICAS COMO INHIBIDORES DE LA PRODUCCION DE PROTEINAS ABETA